These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Production of Dual Inhibitory Hydrolysate by Enzymatic Hydrolysis of Squid Processing By-product.
    Author: Liu Q, Yao Y, Ibrahim MAA, Halawany AME, Yang L, Zhang X.
    Journal: Mar Biotechnol (NY); 2022 Apr; 24(2):293-302. PubMed ID: 35275289.
    Abstract:
    Squid processing by-product contains unutilized abundant proteins. In this study, 6 proteases (pepsin, protamex, trypsin, neutral protease, alkaline protease, and papain) were firstly employed to hydrolyze the squid processing by-product protein. The neutral protease-digested hydrolysate was found to have the most promising ACE (angiotensin-converting enzyme) inhibitory activity. Based on Box-Behnken design, the optimal hydrolysis process was determined to be: 52.4 ℃ of temperature, 5.7 h of time, pH 7.1, and 8151 U/g of enzyme. Under these conditions, the ACE inhibition rate and polypeptide content of the hydrolysate were 84.26% and 229.09 mg/g, respectively. Subsequently, ultrafiltration was performed, and the ACE and renin inhibitory activities of the filtrate (< 1 kDa) were the highest, reaching 87.48 ± 1.76% and 69.72 ± 1.16%, with IC50 values of 1.34 ± 0.12 mg/mL and 1.47 ± 0.06 mg/mL, respectively. However, these activities decreased to 35.15 ± 1.31% and 43.17% ± 1.42%, respectively, after digestion by simulated gastrointestinal juice. Nevertheless, this is the first report representing the neutral protease-digested hydrolysate of squid processing by-product as a potential source of both ACE and renin inhibitors.
    [Abstract] [Full Text] [Related] [New Search]